Anti-tuberculosis (TB) drug resistance is a major public health problem that threatens progress made in TB care and control worldwide. Drug resistance arises due to improper use of antibiotics in chemotherapy of drug-susceptible TB patients. This improper use is a result of a number of actions including, administration of improper treatment regimens and failure to ensure that patients complete the whole course of treatment. Essentially, drug resistance arises in areas with weak TB control programmes. A patient who develops active disease with a drug-resistant TB strain can transmit this form of TB to other individuals.
Globally in 2016, there were an estimated 4.1% of new cases and 19% of previously treated cases with MDR-TB. Drug resistance surveillance data show that of the estimated 490 000 people developed MDR-TB in 2016, 16% died. In spite of increased testing, the number of MDR/RR-TB cases detected only reached 153 000. In 2016, 8 000 patients with extensively drug-resistant TB (XDR-TB) were reported worldwide. To date, 121 countries have reported at least one XDR-TB case. On average, an estimated 6.2% of people with MDR-TB have XDR-TB.
XDR-TB is a form of TB which is resistant to at least four of the core anti-TB drugs. It involves resistance to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance (MDR-TB), in addition to resistance to any of the fluoroquinolones (such as ofloxacin or moxifloxacin) and to at least one of three injectable second-line drugs (amikacin, capreomycin or kanamycin).
490 000cases of MDR-TB estimated among TB patientsGlobal situation
130 000patients with MDR-TB detected and reportedMDR-TB factsheet
8 500 with XDR-TB were enrolled in treatmentMDR-TB factsheet
News, events and meeting reports
28-29 June 2016
Guideline Development Group (GDG) Meeting: Revision of the interim policy on bedaquiline for MDR-TB treatment and special session on delamanid use in children
A Guidelines Development Group composed of tuberculosis experts was convened by WHO’s Global TB Programme to review data from recent studies of patients with drug-resistant TB, treated with bedaquiline and delamanid. The group met in Geneva on 28 and 29 June 2016 to review new data related to pharmacokinetics and pharmoacodynamics, effectiveness and safety, and to consider any relevant revisions to WHO interim policies (released in 2013 and 2014). The recommendations of the expert group on the use of delamanid in children (> 6) and for adolescents will inform upcoming WHO guidance revision. Further data on the use of bedaquiline are being collected and the evidence review is expected to be finalized in the second half of the year.
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients
New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
Updates on situation of drug-resistant TB in Papua New Guinea, with special emphasis on Daru Island
This document provides an update on the progress made since May 2015 and WHO's position to further support the country's efforts
WHO is currently updating this guidance and convened a meeting of the Guideline Development Group in Geneva, Switzerland from 12 to 13 November 2015
- WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
- WHO treatment guidelines for drug-resistant tuberculosis
- Public notice: Guideline Development Group (GDG) Meetings
- Use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents
- Global tuberculosis report
- Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis
- Guidelines for surveillance of drug resistance in tuberculosis - 5th edition
- WHO launches a bedaquiline implementation plan for countries
- Interim policy guidance on bedaquiline
- Interim policy guidance on delamanid